Caladrius Biosciences Inc (NASDAQ:CLBS) – Stock analysts at Dawson James issued their Q1 2020 earnings per share (EPS) estimates for shares of Caladrius Biosciences in a report issued on Monday, August 12th. Dawson James analyst J. Kolbert forecasts that the biotechnology company will post earnings per share of ($0.12) for the quarter. Dawson James also issued estimates for Caladrius Biosciences’ Q2 2020 earnings at ($0.13) EPS, Q3 2020 earnings at ($0.14) EPS and Q4 2020 earnings at ($0.15) EPS.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05).
Several other brokerages also recently weighed in on CLBS. Zacks Investment Research downgraded Caladrius Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday. WBB Securities assumed coverage on Caladrius Biosciences in a research report on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 target price on the stock. ValuEngine upgraded Caladrius Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Caladrius Biosciences in a research report on Sunday, May 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Caladrius Biosciences has a consensus rating of “Buy” and a consensus price target of $8.63.
Shares of CLBS opened at $2.53 on Wednesday. The business’s 50-day moving average is $2.69 and its two-hundred day moving average is $3.28. Caladrius Biosciences has a fifty-two week low of $2.16 and a fifty-two week high of $6.83.
Large investors have recently bought and sold shares of the company. Wesbanco Bank Inc. acquired a new stake in shares of Caladrius Biosciences during the 1st quarter valued at about $36,000. Vanguard Group Inc. grew its position in shares of Caladrius Biosciences by 7.6% during the 2nd quarter. Vanguard Group Inc. now owns 207,973 shares of the biotechnology company’s stock valued at $474,000 after acquiring an additional 14,740 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Caladrius Biosciences by 20.6% during the 2nd quarter. Renaissance Technologies LLC now owns 380,336 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 64,988 shares during the period. Hedge funds and other institutional investors own 7.45% of the company’s stock.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Featured Article: Gross Domestic Product (GDP)
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.